A Study to Assess LBL-007 in Combination With Toripalimab in Subjects With Advanced Melanoma

• Status: Recruiting
• Trial end date: 2023-04-20
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center ,open-label, single-arm,dose-escalation,and extended phase I of LBL-007 in combination with Toripalimab. The study is designed to assess the safety, tolerability and efficacy of LBL-007 in combination with Toripalimab in the treatment of unresectable or metastatic melanoma(including Cutaneous melanoma, Acral melanoma, Mucosal melanoma, and melanoma of unknown primary）。

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing Leads Biolabs Co.,Ltd

Criteria

Inclusion Criteria:

1. Willingness to provide written informed consent and follow the study treatment plan and visit plan;

2. Aged ≥ 18 years at time of signing informed consent, male or female;

3. Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1;

4. Have life expectancy of at least 12 weeks ;

5. Subject with at least one measurable tumor lesion,according to the evaluation standard of solid tumor efficacy (RECIST 1.1).

Exclusion criteria:

1. Subjects are allergic to LBL-007, PD-1 and similar compounds or any component in the prescription;

2. Subjects with active central nervous system metastases (regardless of whether they have received treatment), including symptomatic brain metastases, meningeal metastases, or spinal cord compression, but asymptomatic brain metastases (no progression and/or at least 4 weeks after radiotherapy) No neurological symptoms or signs after surgical resection, and dexamethasone or mannitol treatment is not required);

3. Have received major surgery within 4 weeks before the first administration;

4. Subjects can not tolerate intravenous administration and have difficulty in venous blood collection (if there is a history of fainting needles and bleeding);

5. Women during pregnancy or lactation;